20010803
 Aventis Reports Robust Earnings For 2nd Period, on Stalwart Drugs   By By Carolyn Whelan, The Wall Street Journal,  Aug 3, 2001  Aventis said second-quarter net profit for its core pharmaceuticals business rose 31% to 391 million euros ($345 million) -- beating market forecasts of around 380.5 million euros -- as sales rose 8% to 4.45 billion euros. Growth was driven by unexpectedly high sales of Aventis's best-selling Lovenox, for thrombosis, cancer drug Taxotere and antihistamine Allegra. Including earnings from its soon-to-be-sold agricultural businesses, second-quarter net profit rose 11% to 413 million euros.   
